Neurostat

Neurostat is a clinical-stage biotechnology company headquartered in Seoul, South Korea, specializing in the development of neuroprotective treatments for acute central nervous system injuries. The company's primary focus is on Traumatic Brain Injury (TBI) and Spinal Cord Injury (SCI), conditions with limited therapeutic options. Its lead candidate, Neurostat, is a specialized formulation of cyclosporine that targets the mitochondrial permeability transition pore (mPTP) to prevent mitochondrial dysfunction and subsequent neuronal loss. By inhibiting cyclophilin D, the therapy aims to mitigate the secondary injury cascade following physical trauma to the brain or spine. Neurostat is currently advancing its lead program through Phase 2 clinical development while exploring further applications in neurodegeneration.